Global joint development of immuno-cancer drugs under the mechanism of double fusion antibodies and acquisition of exclusive sales rights

Dong-A ST announced on the 21st that it has signed a license agreement with Kanaph Therapeutics to license candidate substances for immuno-cancer drugs under the dual fusion antibody mechanism. Dong-AST will introduce global joint research and development and exclusive sales rights of preclinical immuno-cancer drug candidates held by Kanaph Therapeutics, a domestic pharmaceutical bio-venture.

Dong-AST will pay Kanaph 5 billion won in advance and up to 18 billion won in additional payments depending on the development milestone. It also plans to pay up t